These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Gustavsen KM; Bradley MH; Wright AL Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S11-5. PubMed ID: 19843393 [TBL] [Abstract][Full Text] [Related]
25. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec; 2004 Oct; 79(40):358-65. PubMed ID: 15631012 [No Abstract] [Full Text] [Related]
26. Major progress toward eliminating lymphatic filariasis. Ottesen EA N Engl J Med; 2002 Dec; 347(23):1885-6. PubMed ID: 12466515 [No Abstract] [Full Text] [Related]
29. The role of medicine donations in the global programme for the elimination of lymphatic filariasis. Williams T; Taylor R; Iwamoto M; Hida T; Gusovsky F Int Health; 2020 Dec; 13(Suppl 1):S39-S43. PubMed ID: 33349878 [TBL] [Abstract][Full Text] [Related]
30. Two decades of public health achievements in lymphatic filariasis (2000-2020): reflections, progress and future challenges. Malecela M; Gyapong J; Ramaiah KD; Molyneux D Int Health; 2020 Dec; 13(Suppl 1):S1-S2. PubMed ID: 33349873 [No Abstract] [Full Text] [Related]
31. Current practices in the management of lymphatic filariasis. Bockarie MJ; Taylor MJ; Gyapong JO Expert Rev Anti Infect Ther; 2009 Jun; 7(5):595-605. PubMed ID: 19485799 [TBL] [Abstract][Full Text] [Related]
32. The sharp end - experiences from the Tanzanian programme for the elimination of lymphatic filariasis: notes from the end of the road. Malecela MN; Mwingira U; Mwakitalu ME; Kabali C; Michael E; Mackenzie CD Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S53-7. PubMed ID: 19843398 [TBL] [Abstract][Full Text] [Related]
33. India tackles lymphatic filariasis. Bagcchi S Lancet Infect Dis; 2015 Apr; 15(4):380. PubMed ID: 25809895 [TBL] [Abstract][Full Text] [Related]
34. Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis. Hooper PJ; Chu BK; Mikhailov A; Ottesen EA; Bradley M PLoS Negl Trop Dis; 2014 Nov; 8(11):e3333. PubMed ID: 25411843 [TBL] [Abstract][Full Text] [Related]
35. Managing morbidity and preventing disability in the Global Programme to Eliminate Lymphatic Filariasis: WHO position statement. Wkly Epidemiol Rec; 2011 Dec; 86(51-52):581-5. PubMed ID: 22191103 [No Abstract] [Full Text] [Related]
36. Lymphatic filariasis: constraints ahead. Mishra CP; Singh N Indian J Public Health; 2003; 47(1):27-30. PubMed ID: 14723292 [No Abstract] [Full Text] [Related]
37. Mass drug administration to eliminate lymphatic filariasis in India. Ramaiah KD; Das PK Trends Parasitol; 2004 Nov; 20(11):499-502. PubMed ID: 15471698 [TBL] [Abstract][Full Text] [Related]
38. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Bockarie MJ; Deb RM Curr Opin Infect Dis; 2010 Dec; 23(6):617-20. PubMed ID: 20847694 [TBL] [Abstract][Full Text] [Related]
39. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107 [No Abstract] [Full Text] [Related]